期刊
TRENDS IN CELL BIOLOGY
卷 26, 期 12, 页码 906-917出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcb.2016.07.002
关键词
-
类别
资金
- NIH [CA157740, CA206005]
- JJR Foundation
- William A, Spivak Fund
- Fridolin Charitable Trust
- American Cancer Society Research Scholar Award
- Leukemia & Lymphoma Society Career Development Award
- Irma T. Hirschl/Monique Weill-Caulier Trust Research Award
- March of Dimes Foundation [5-FY11-74, 1-FY13-416]
- Developmental Research Pilot Project Program within the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai
Cellular commitment to the mitochondria! pathway of apoptosis is accomplished when proapoptotic B cell chronic lymphocytic leukemia/lymphoma (BCL)-2 proteins compromise mitochondrial integrity through the process of mitochondria! outer membrane permeabilization (MOMP). For nearly three decades, intensive efforts focused on the identification and interactions of two key proapoptotic BCL-2 proteins: BCL-2 antagonist killer (BAK) and BCL-2-associated X (BAX). Indeed, we now have critical insights into which BCL-2 proteins interact with BAK/BAX to either preserve survival or initiate MOMP. In contrast, while mitochondria are targeted by BAK/BAX, a molecular understanding of how these organelles govern BAK/BAX function remains less clear. Here, we integrate recent mechanistic insights of proapoptotic BCL-2 protein function in the context of mitochondria! environment, and discuss current and potential pharmacological opportunities to control MOMP in disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据